PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE POTENTIAL-DRUG INTERACTION BETWEEN VENLAFAXINE AND DIAZEPAM

被引:36
作者
TROY, SM
LUCKI, I
PEIRGIES, AA
PARKER, VD
KLOCKOWSKI, PM
CHIANG, ST
机构
[1] UNIV PENN,DEPT PSYCHIAT,PHILADELPHIA,PA 19104
[2] UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104
[3] ONEIDA RES SERV INC,WHITESBORO,NY
关键词
D O I
10.1002/j.1552-4604.1995.tb04082.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To assess possible pharmacokinetic and pharmacodynamic interactions between the antidepressant venlafaxine and diazepam, a randomized, two-period, crossover study was conducted in 18 men. Multiple-dose venlafaxine (50 mg every 8 hours) or placebo (double-blind) was given for 10 days; on day 4 a single placebo dose (same appearance as diazepam capsule, single-blind) was given; and on day 5 a single dose of diazepam (10 mg) was given. Pharmacokinetic data indicated that diazepam had no significant effect on venlafaxine or O-desmethylvenlafaxine disposition. Diazepam pharmacokinetics were minimally changed in the presence of venlafaxine, Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (V-z/f) increased (0.85 +/- 0.28 Versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng . h/mL; P = .02), Venlafaxine did not alter desmethyldiazepam pharmacokinetics, Pharmacodynamic data showed a statistically significant diazepam-venlafaxine interaction for only one of the eight psychometric tests given. Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments, The observed pharmacokinetic and pharmacodynamic interactions between diazepam and venlafaxine were small and probably clinically insignificant.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 22 条
[1]  
EVANS WE, 1986, APPL PHARMACOKINETIC, P639
[2]  
GARATTINI S, 1973, BENZODIAZEPINES, P27
[3]   DOSE-RESPONSE ANALYSIS OF THE BEHAVIORAL-EFFECTS OF DIAZEPAM .1. LEARNING AND MEMORY [J].
GHONEIM, MM ;
HINRICHS, JV ;
MEWALDT, SP .
PSYCHOPHARMACOLOGY, 1984, 82 (04) :291-295
[4]  
GHONEIM MM, 1986, J CLIN PSYCHOPHARM, V6, P75
[5]   INFLUENCE OF CIMETIDINE ON ORAL DIAZEPAM ELIMINATION WITH MEASUREMENT OF SUBSEQUENT COGNITIVE CHANGE [J].
GOUGH, PA ;
CURRY, SH ;
ARAUJO, OE ;
ROBINSON, JD ;
DALLMAN, JJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 14 (05) :739-742
[6]  
HASKINS J T, 1984, Society for Neuroscience Abstracts, V10, P262
[7]  
KAHN A, 1991, PSYCHOPHARMACOL BULL, V27, P141
[8]   INTRODUCTION OF A COMPOSITE PARAMETER TO THE PHARMACOKINETICS OF VENLAFAXINE AND ITS ACTIVE O-DESMETHYL METABOLITE [J].
KLAMERUS, KJ ;
MALONEY, K ;
RUDOLPH, RL ;
SISENWINE, SF ;
JUSKO, WJ ;
CHIANG, ST .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (08) :716-724
[9]   PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION STUDY OF DIAZEPAM AND METOPROLOL [J].
KLOTZ, U ;
REIMANN, IW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (02) :223-226
[10]  
LUCKI I, 1986, PSYCHOPHARMACOLOGY, V88, P426